Suggested remit: To appraise the clinical and cost effectiveness of ixazomib in combination with lenalidomide and dexamethasone within its marketing authorisation for untreated multiple myeloma in people for whom a stem cell transplant is unsuitable.
Topic is suspended
 
Status Suspended
Decision Selected
Process STA 2018
ID number 1170

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
12 June 2020 Suspended. Topic is suspended
12 June 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma. For information, the company have advised that they will not be submitting a Marketing Authorisation Application to the European Medicines Agency for this indication in line with previously communicated timelines. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
03 July 2018 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma. Following an update from the company, the timelines for this appraisal are to be confirmed whilst the company await the outcome of the next planned interim analysis of the ongoing TOURMALINE-MM2 trial being undertaken in this indication. NICE will continue to monitor development and will update interested parties as and when the situation changes.
25 April 2018 - 24 May 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
19 September 2016 In progress. DH referral received

For further information on our processes and methods, please see our CHTE processes and methods manual